)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Molecular Partners (MOLN) investor relations material
Molecular Partners Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary30 Oct, 2025
Executive summary
Clinical-stage biotech focused on DARPin therapeutics, with operations in Switzerland and the US, and a strong cash position of CHF 105M as of September 30, 2025, providing runway through 2028.
Proprietary platforms include Radio-DARPins and next-gen immune cell engagers, with global partnerships such as Orano Med to advance up to ten targeted radiotherapy programs.
Lead assets MP0712 (targeted radiotherapy for SCLC/NECs) and MP0533 (tetra-specific T-cell engager for AML) are advancing through clinical and preclinical stages, with IND filed for MP0712 and Phase 1 trial expected to start before end of 2025.
Appointment of Martin Steegmaier, PhD, as CSO and Executive Committee member effective October 1, 2025.
Protocol approved for Phase 2 investigator-initiated trial of FAP x CD40 agonist MP0317 in advanced cholangiocarcinoma.
Financial highlights
CHF 105M in cash and short-term deposits as of September 30, 2025, supporting operations and R&D through key value inflection points until 2028.
Expected total operating expenses for full year 2025 are CHF 55–60 million, including around CHF 6 million in non-cash costs.
Strategic review of operations completed, further extending financial runway.
Outlook and guidance
First-in-human Phase 1 study for MP0712 expected to start in 2025, with initial safety data anticipated in H1 2026.
Early imaging data for MP0712 to be presented at TRP 2025, with full data at TWC 2026.
Progression of second RDT program MP0726 and nomination of additional 212Pb x RDT programs in 2026.
Initial data from amended dosing scheme for MP0533 (cohort 9) at ASH 2025; combo trials initiation in 2026 pending data.
Preclinical update on CD3 Switch-DARPin T cell engager program at SITC 2025.
MP0712 imaging data: what predicts 212Pb efficacy?
What defines ideal MP0533 patient profile?
What drives selection of new RDT targets?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Molecular Partners earnings date
Q4 202512 Mar, 2026
Next Molecular Partners earnings date
Q4 202512 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Schlieren, canton of Zürich, Switzerland. Founded in 2004 by researchers from the University of Zürich, the company specializes in the development of a novel class of custom-built protein therapeutics known as Designed Ankyrin Repeat Proteins (DARPins). These DARPins are versatile and potent small-protein therapies with applications across various disease areas, including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners has established itself in the biotechnology industry by leveraging its DARPin platform to create therapies that aim to surpass the limitations of current treatment options. Molecular Partners AG's shares are listed on the SIX Swiss Exchange and the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage